Citations

Clear

9383 citation(s) found for "Thomas, PS".

Risk factors for distal junctional failure following three-column osteotomy for cervical deformity correction
Mikula, Anthony L. , Choy, Winward , Pennington, Zach , Semonche, Alexa , Mazur-Hart, David J. , Nguyen, Terry H., Deviren, Vedat , Pennington, Zach , Wozny, Thomas A. , Kim, Jaemin, Clark, Allan , Ames, Christopher Pearson

Mayo Clinic

Journal of Neurosurgery: Spine | April 5, 2025 | Volume: 42 | Issue: 6 | Pages: 697-704

10.3171/2025.1.spine241325 | PMID 40184675 Get It

OBJECTIVE The purpose of this study was to determine risk factors for distal junctional failure (DJF) following three-column osteotomy (3CO) for the correction of cervical deformity. METHODS A retrospective review was performed of patients who underwent a cervical or upper thoracic 3CO for cervical deformity correction by the senior author from 2008 to 2023. The main outcome of interest was DJF, defined as revision surgery with extension of the distal end of the fusion construct. Patients were excluded if the lowest instrumented vertebra (LIV) was the sacrum/pelvis, and if patients had prior autofusion throughout the distal part of the spine to the sacrum (e.g., ankylosing spondylitis). The minimum follow-up duration was 1 year. RESULTS One hundred fourteen patients were identified who underwent a cervical or upper thoracic 3CO for cervical deformity correction, 41 of whom met inclusion criteria for this study. The median patient age was 66 years, median BMI was 27, and 61% were male. Ten patients (24%) experienced DJF, requiring reoperation and distal extension of the construct to the pelvis in 9 cases and to L1 in 1 case. On univariable analysis, patients who experienced DJF compared with those who did not were more likely to be female (80% vs 35%, p = 0.007), had lower LIV Hounsfield units (HUs; 127 vs 167, p = 0.041), were less likely to have an LIV in a small autofused segment (10% vs 45%, p = 0.02), had an LIV that was closer to the first lordotic level (one level above vs three, p = 0.043), and had a longer length of fusion (17 vs 13 levels, p = 0.033). A stepwise multivariable regression model showed that having an LIV closer to the first lordotic vertebra was the only statistically significant predictor of DJF (OR 0.49, p = 0.013) and low LIV HUs did not reach statistical significance (OR 0.97, p = 0.09). CONCLUSIONS Patients with cervical deformity undergoing a 3CO are at higher risk for DJF with constructs terminating near the first lordotic vertebra. While LIV selection is complex and patient specific, choosing an LIV at least two levels above the first lordotic vertebra may help prevent DJF.
Assessment and Impact of Age on the Safety and Efficacy of Etrasimod in Patients With Ulcerative Colitis: A Post Hoc Analysis of Data From the ELEVATE UC Clinical Program
Lichtenstein, Gary R. , Allegretti, Jessica R. , Irving, Peter M., Charabaty, Aline , Kuehbacher, Tanja, Bananis, Eustratios , Woolcott, John , Dalam, Alexis B, Lazin, Krisztina , Keating, Michael J. , McDonnell, Aoibhinn , Danese, Silvio , Loftus, Edward V. , Banerjee, Rupa , Danese, Silvio

Mayo Clinic

Inflammatory Bowel Diseases | April 4, 2025 | Volume: 31 | Issue: 9 | Pages: 2352-2362

10.1093/ibd/izae308 | PMID 40184206 Get It

Abstract Background Patient age can impact the safety and efficacy of ulcerative colitis (UC) treatments. Etrasimod is an oral, once daily (QD), selective sphingosine 1-phosphate1,4,5 receptor modulator for the treatment of moderately to severely active UC. Here, we evaluate the impact of age on etrasimod safety and efficacy in patients with UC in the phase 3 ELEVATE UC clinical program. Methods Data were pooled from ELEVATE UC 52 and ELEVATE UC 12 in patients receiving etrasimod 2 mg QD or placebo. Proportions and incidence rates (IRs) per 100 patient-years of treatment-emergent adverse events (AEs) were stratified by age (<40, 40-59, and ≥60 years). With the same age stratifications, efficacy was evaluated in patients with baseline Modified Mayo scores of 5-9 and 4-9 for the primary efficacy endpoint (clinical remission) and secondary efficacy endpoints. Results Overall, 787 patients were enrolled (<40 years, n = 420 [53.4%]; 40-59 years, n = 276 [35.1%]; and ≥60 years, n = 91 [11.6%]). Arthralgia, fatigue, and hypertension IRs were higher in older patients, irrespective of treatment. Serious AEs and AEs leading to treatment discontinuation were low and consistent across age groups. Significantly more patients receiving etrasimod 2 mg QD vs placebo achieved efficacy endpoints, regardless of age. Conclusions The safety profile of etrasimod 2 mg QD in the ELEVATE UC population was consistent across age groups, with no change in the incidence of AEs. Patients receiving etrasimod vs placebo showed significant clinical benefit, regardless of age. ClinicalTrials.gov NCT03945188; NCT03996369.
Evaluating nurse preferences for a novel on-body delivery system vs. manual syringes for large-volume subcutaneous drug administration: a survey study
Desai, Mehul , Gorski, Lisa A., Miles, A. , Sterlin, Valentina, Curry, Nicole, Faiman, Beth M , Miles, Ashley, Curry, Nicole

Mayo Clinic

Drug Delivery | April 4, 2025 | Volume: 32 | Issue: 1 | Pages: No page available

10.1080/10717544.2025.2484278 | PMID 40177924 Get It

Multi-cancer early detection tests: Attributes for clinical implementation
Ebbert, Jon O. , Hawk, Ernest T. , Chambers, Christopher V., Tempero, Margaret A., Fishman, Elliot K., Ravenell, Joseph , Rego, Seema , Ravenell, Jospeh E , Tempero, Margaret A. , Fishman, Elliot K. , Beer, Tomasz M.

Mayo Clinic

Cancer Biomarkers | April 2, 2025 | Volume: 42 | Issue: 2 | Pages: No page available

10.1177/18758592241297849 | PMID 40171802 Get It

Guideline-recommended screening programs exist for only a few single-cancer types, and these cancers represent less than one-half of all new cancer cases diagnosed each year in the U.S. In addition, these “single-cancer” standard of care (SoC) screening tests vary in accuracy, adherence, and effectiveness, though all are generally understood to lead to reductions in cancer-related mortality. Recent advances in high-throughput technologies and machine learning have facilitated the development of blood-based multi-cancer early detection (MCED) tests. The opportunity for early detection of multiple cancers with a single blood test holds promise in addressing the current unmet need in cancer screening. By complementing existing SoC screening, MCED tests have the potential to detect a wide range of cancers at earlier stages when patients are asymptomatic, enabling more effective treatment options and improved cancer outcomes. MCED tests are positioned to be utilized as a complementary screening tool to improve screening adherence at the population level, to broaden screening availability for individuals who are not adherent with SoC screening programs, as well as for those who may harbor cancers that do not have SoC testing available. Published work to date has primarily focused on test performance relating to sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV). MCED tests will require approval through the pre-market approval pathway from the United States Food and Drug Administration. Additional studies will be needed to demonstrate clinical utility (i.e., improvements in health outcomes) and establish optimal implementation strategies, (i.e., testing intervals), follow-up and logistics of shared decision making. Here, we propose core attributes of MCED testing for which clinical data are needed to ideally position MCED testing for widespread use in clinical practice.
Long-Term Patient-Reported Bowel and Urinary Quality of Life in Patients Treated with Intensity-Modulated Radiotherapy Versus Intensity-Modulated Proton Therapy for Localized Prostate Cancer
Gergelis, Kimberly R. , Bai, Miao , Ma, Jiasen , Stish, Bradley J. , Davis, Brian J. , Pisansky, Thomas M. , Whitaker, Thomas J. , Choo, Richard , Davis, Brian J , Bai, Miao , Routman, David M.

Mayo Clinic

Current Oncology | April 2, 2025 | Volume: 32 | Issue: 4 | Pages: 212

10.3390/curroncol32040212 | PMID 40277768 Get It

Purpose: This study aimed to compare long-term patient-reported outcomes in bowel and urinary domains between intensity-modulated radiotherapy (IMRT) and intensity-modulated proton therapy (IMPT) for localized prostate cancer. Methods and Materials: Patients with clinical T1–T2 prostate cancer receiving IMRT or IMPT at a tertiary cancer center from 2015–2018 were analyzed to determine the changes in the prospectively collected bowel function (BF), urinary irritative/obstructive symptoms (UO), and urinary incontinence (UI) domains of EPIC-26. The mean changes in EPIC-26 scores were evaluated from pretreatment to 24 months post-radiotherapy for each modality. A score change >50% of the baseline standard deviation was considered a clinically meaningful change. Results: A total of 82 patients treated with IMRT (52.2%) and 56 patients treated with IMPT (53.3%) completed the questionnaire at baseline and 24 months post-RT. There were no baseline differences in domain scores between treatment modalities. At 24 months post-radiotherapy, there was a significant and clinically meaningful decline in the BF mean score in the IMRT cohort (−4.52 (range −50, 29.17), p = 0.003), whereas the decline in BF score did not reach clinical relevance or significance (−1.88 (range −37.5, 50), p = 0.046) when accounting for the Bonferroni adjustment in the IMPT cohort. A higher proportion of patients treated with IMRT had a clinically relevant reduction in BF when compared with IMPT (47.37% vs. 25.93%, p = 0.017). The mean changes in the UI and UO scores of the IMRT and IMPT cohorts were neither statically significant nor clinically relevant. Conclusions: IMPT leads to a smaller decrease in BF than IMRT at 24 months post-RT, while there was no differential effect on UO and UI.
Leading with options or issues to support purposeful shared decision-making in clinical practice
Loor-Torres, Ricardo , Bui, Yvonne , Steffensen, Karina Dahl , Heen, Anja Fog , Agoritsas, Thomas , Kunneman, Marleen , Carley, Meg , Cabezas, Esteban , Stacey, Dawn , Hargraves, Ian , Carley, Meg E , Montori, Victor M , Stacey, Dawn , Montori, Víctor M.

Mayo Clinic

BMJ Evidence-Based Medicine | April 1, 2025 | Volume: 30 | Issue: 6 | Pages: 409-412

10.1136/bmjebm-2024-113322 | PMID 40169187 Get It

State of the Art of Artificial Intelligence in Clinical Electrophysiology in 2025: A Scientific Statement of the European Heart Rhythm Association (EHRA) of the ESC, the Heart Rhythm Society (HRS), and the ESC Working Group on E-Cardiology
Svennberg, Emma , Han, Janet K. , Caiani, Enrico G. , Engelhardt, Sandy , Friedman, Paul A. , Garcia, Rodrigue , Ghanbari, Hamid , Hindricks, Gerhard , Man, Sharon , Hansen, Jacob Tfelt, Barker, Joseph, Casado-Arroyo, Ruben, Chatterjee, Neal A, Conte, Giulio, Diederichsen, Søren Zöga, Linz, Dominik, Mahtani, Arun Umesh, Zorzi, Alessandro, Tfelt‐Hansen, Jacob , Diederichsen, Søren Zöga , Ernst, Sabine , Friedman, Paul A , Garcia, Rodrigue , Hindricks, Gerhard , Man, Sharon H , Millet, José , Narayan, Sanjiv M , Ng, G. André , Noseworthy, Peter A , Tjong, Fleur V Y , Ramírez, Julia , Singh, Jagmeet P , Trayanova, Natalia A , Duncker, David , Tfelt-Hansen, Jacob , Diederichsen, Søren Z , Ernst, Sabine , Narayan, Sanjiv M. , Noseworthy, Peter A. , Ramírez, Julia , Trayanova, Natalia A. , Duncker, David , Barker, Joseph, Casado-Arroyo, Ruben, Chatterjee, Neal A, Conte, Giulio, Linz, Dominik, Mahtani, Arun Umesh, Zorzi, Alessandro

Mayo Clinic

Europace | March 31, 2025 | Volume: 27 | Issue: 5 | Pages: No page available

10.1093/europace/euaf071 | PMID 40163651 Get It

Abstract Aims Artificial intelligence (AI) has the potential to transform cardiac electrophysiology (EP), particularly in arrhythmia detection, procedural optimization, and patient outcome prediction. However, a standardized approach to reporting and understanding AI-related research in EP is lacking. This scientific statement aims to develop and apply a checklist for AI-related research reporting in EP to enhance transparency, reproducibility, and understandability in the field. Methods and results An AI checklist specific to EP was developed with expert input from the writing group and voted on using a modified Delphi process, leading to the development of a 29-item checklist. The checklist was subsequently applied to assess reporting practices to identify areas where improvements could be made and provide an overview of the state of the art in AI-related EP research in three domains from May 2021 until May 2024: atrial fibrillation (AF) management, sudden cardiac death (SCD), and EP lab applications. The EHRA AI checklist was applied to 31 studies in AF management, 18 studies in SCD, and 6 studies in EP lab applications. Results differed between the different domains, but in no domain reporting of a specific item exceeded 55% of included papers. Key areas such as trial registration, participant details, data handling, and training performance were underreported (<20%). The checklist application highlighted areas where reporting practices could be improved to promote clearer, more comprehensive AI research in EP. Conclusion The EHRA AI checklist provides a structured framework for reporting AI research in EP. Its use can improve understanding but also enhance the reproducibility and transparency of AI studies, fostering more robust and reliable integration of AI into clinical EP practice.
EP4.7 Two-Year Minimum Outcomes of Arthroscopic Subchondroplasty for Acetabular Subchondral Cysts Demonstrates 62.1% Arthroplasty-Free Survivorship: Smaller Cyst Size Predicts Survivorship
Vogel, Michael , Alvero, Alexander , Cotter, Eric J. , Alter, Thomas D. , Nho, Shane, Cervantes, Jesus, Chapman, Reagan S. , Nho, Shane J. , Cervantes, Jesus

Mayo Clinic

Journal of Hip Preservation Surgery | March 31, 2025 | Volume: 12 | Issue: Supplement_1 | Pages: i80-i81

10.1093/jhps/hnaf011.260 Get It

Abstract Background: Prior studies have evaluated the efficacy of subchondroplasty for the management of subchondral cysts of the knee, yet few studies to date evaluate minimum 2-year outcomes following subchondroplasty of the acetabulum. Purpose: The purpose of this study was to evaluate minimum two-year outcomes following arthroscopic subchondroplasty for the treatment of acetabular subchondral cysts and to identify variables associated with total hip arthroplasty (THA) conversion following subchondroplasty. Study Design: Cases Series, Level of Evidence IV. Methods: A retrospective review of prospectively maintained data was performed on patients who underwent primary hip arthroscopy May 2019 to September 2021 by a single surgeon. Consecutive patients who underwent subchondroplasty for acetabular subchondral cysts with minimum two-year follow-up were identified. Demographics, magnetic resonance imaging (MRI), intraoperative findings, and clinical outcomes were evaluated. Cross-sectional area of the subchondral cysts was measured on MRI. Clinical outcomes included Hip Outcome Score–Activities of Daily Living (HOS-ADL), HOS–Sports Subscale (HOS-SS), international Hip Outcome Score-12 (iHOT-12), and visual analog scale for pain (VAS-Pain). Conversion to THA was recorded. The patients who converted to THA were compared to those who did not. Continuous variables associated with THA conversion were analyzed with receiver operating characteristic (ROC) curves to identify thresholds associated with THA conversion. Results: Twenty-nine patients underwent subchondroplasty for acetabular subchondral cysts with minimum two-year follow up (age: 48.2±11.1 years, body mass index: 29.9±6.6kg/m2, 52.0% female). The THA-free survivorship rate was 62.1%. Patients who achieved THA-free survivorship had smaller subchondral cysts (88.5±59.2 mm2 vs. 147.1±54.8, P=0.013) and a lower prevalence of high-grade femoral head chondral defects (16.7% vs. 54.5%, P=0.048) compared to patients who converted to THA. ROC analysis identified patients with a subchondral cyst <133 mm2 were 21.3 times more likely to achieve THA-free survivorship (P=0.001). The THA-free survivors demonstrated significant improvements across all measured PROs (P≤0.015). Conclusions: Subchondroplasty for acetabular subchondral cysts demonstrated a 62.1% THA-free survivorship at minimum 2-year follow-up, with survivors demonstrating significantly improved PROs. Patients with cysts <133 mm2 were 21.3 times more likely to achieve THA-free survivorship than patients with larger cysts. Keywords: Hip, Acetabulum, Subchondral Cysts, Subchondroplasty
Long-Term Effects of Mavacamten on Patients Based on Hypertrophic Cardiomyopathy Pathogenic Genetic Variant Status: Insights From VALOR-HCM Trial
Desai, Milind Y. , Owens, Anjali , Saberi, Sara , Wang, Andrew , Wolski, Kathy, Cremer, Paul , Lakdawala, Neal K. , Tower‐Rader, Albree, Zenker, Mark, Geske, Jeffrey B. , Naidu, Srihari S. , Lampl, Kathy, Nissen, Steven E. , Investigators, for the VALOR-HCM, Wolski, Kathy , Cremer, Paul C , Tower-Rader, Albree , Sherrid, Mark , Geske, Jeffrey B , Fermin, David , Naidu, Srihari S , Nissen, Steven E , Saberi, Sara , Wang, Andrew , Zenker, Mark, Sherrid, Mark V. , Fermin, David , Investigators, for the VALOR-HCM

Mayo Clinic

Circulation: Genomic and Precision Medicine | March 31, 2025 | Volume: 18 | Issue: 3 | Pages: No page available

10.1161/circgen.125.005100 | PMID 40163785 Get It